Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 22.21B +11.2% |
| Revenue (ttm) | 8.58B +4.8% |
| Net Income | 1.37B -0.4% |
| EPS | 9.35 -0.8% |
| Shares Out | n/a |
| PE Ratio | 16.20 |
| Forward PE | 13.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,548 |
| Average Volume | 912 |
| Open | 150.95 |
| Previous Close | 149.10 |
| Day's Range | 145.45 - 152.05 |
| 52-Week Range | 99.00 - 162.30 |
| Beta | 0.13 |
| RSI | 52.14 |
| Earnings Date | Feb 6, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Oppenheimer Raises Price Target for Biogen (BIIB) to $225 | BIIB Stock News
Oppenheimer Raises Price Target for Biogen (BIIB) to $225 | BIIB Stock News
REGIONS FINANCIAL CORP Buys 1,237 Shares of Biogen Inc (BIIB)
REGIONS FINANCIAL CORP Buys 1,237 Shares of Biogen Inc (BIIB)
FIRST HORIZON CORP Buys 169 Shares of Biogen Inc (BIIB)
FIRST HORIZON CORP Buys 169 Shares of Biogen Inc (BIIB)
Forum Financial Management, LP Buys 3,039 Shares of Biogen Inc (BIIB)
Forum Financial Management, LP Buys 3,039 Shares of Biogen Inc (BIIB)
ActivePassive U.S. Equity ETF Buys 3,907 Shares of Biogen Inc (BIIB)
ActivePassive U.S. Equity ETF Buys 3,907 Shares of Biogen Inc (BIIB)
Convergence Long/Short Equity ETF Buys 8,925 Shares of Biogen Inc (BIIB)
Convergence Long/Short Equity ETF Buys 8,925 Shares of Biogen Inc (BIIB)
Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE
WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment...
Biogen (BIIB) Achieves Breakthrough Therapy Status for CLE Treatment
Biogen (BIIB) Achieves Breakthrough Therapy Status for CLE Treatment
Biogen Inc.: Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLiti...
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifi...
Citigroup Maintains Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News
Citigroup Maintains Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News
GF FUND MANAGEMENT CO. LTD. Sells 29,529 Shares of Biogen Inc (BIIB)
GF FUND MANAGEMENT CO. LTD. Sells 29,529 Shares of Biogen Inc (BIIB)
FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd, (4523.T, ESALY.PK, ESALF.PK), a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the U.S. Food and Drug Administration (FDA) has accepted for priori...
FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Application
FDA Reviews Biogen's (BIIB) Alzheimer's Drug Lecanemab-irmb Application
FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector
(RTTNews) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License Applicatio...
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
Goldman Sachs Strategic Factor Allocation Fund Buys 2,486 Shares of Biogen Inc (BIIB)
Goldman Sachs Strategic Factor Allocation Fund Buys 2,486 Shares of Biogen Inc (BIIB)
Bridgewater Advisors Inc. Buys 1,212 Shares of Biogen Inc (BIIB)
Bridgewater Advisors Inc. Buys 1,212 Shares of Biogen Inc (BIIB)
Looking Into Biogen Inc's Recent Short Interest
Biogen Inc's (NYSE: BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data, there are now 4.47 million shares sold short , which is 3....
JACKSON THORNTON WEALTH MANAGEMENT, LLC Buys 1,297 Shares of Biogen Inc (BIIB)
JACKSON THORNTON WEALTH MANAGEMENT, LLC Buys 1,297 Shares of Biogen Inc (BIIB)
Apollon Wealth Management, LLC Buys 1,421 Shares of Biogen Inc (BIIB)
Apollon Wealth Management, LLC Buys 1,421 Shares of Biogen Inc (BIIB)
Biogen Inc (BIIB) Shares Up 3.16% on Jan 21
Biogen Inc (BIIB) Shares Up 3.16% on Jan 21